Advertisement

Archives of Dermatological Research

, Volume 311, Issue 8, pp 607–613 | Cite as

Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: a retrospective case series

  • Maryam Nasimi
  • Narges Ghandi
  • Robabeh Abedini
  • Azadeh Mirshamsi
  • Safoura ShakoeiEmail author
  • Hassan Seirafi
Original Paper
  • 41 Downloads

Abstract

Contact immunotherapy with diphenylcyclopropenone (DPCP) and anthralin is considered the treatment option for extensive alopecia areata (AA) unresponsive to DPCP immunotherapy alone. Only one study has described the efficacy of combination therapy; therefore, we investigated whether topical DPCP and anthralin can promote hair regrowth in DPCP-non responders. In this retrospective case-series we analyzed the efficacy and side effects of DPCP with anthralin in AA patients who did not respond to several months of treatment with DPCP alone. Thirty-two DPCP-nonresponsive AA patients were treated with DPCP and anthralin for the average of 8.3 ± 3.8 (3–17) months. During the treatment, 40.62% of patients (13 patients out of 32) had terminal hair regrowth. The mean of hair regrowth rate was 41%; it was mainly as partial hair regrowth (˂ 50%) and 27.27% of cases achieved > 50% terminal hair regrowth. Treatment response strongly related to the duration of combination therapy (p value ˂ 0.001), but we did not find any relation with other demographic characteristics. The first signs of response to treatment were noticed 2–12 months (5.5 ± 3.4) after initiation of combination therapy while there was a positive correlation among the duration of treatment and percentage of hair regrowth (p < 0.001). The most common complication was bullae (25%), and the least frequent side effect was generalized pruritus (3.1%). The combination therapy with DPCP and anthralin could be effective to treat DPCP non-responder AA patients. Additionally, the higher treatment response could be achieved by longer treatment duration.

Keywords

Alopecia areata Diphenylcyclopropenone Anthralin Immunotherapy Side effects 

Notes

Funding

This research has not any funding source.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study was approved by the Ethics Research Committee of the School of Public Health, Tehran University of Medical Sciences. (IR.TUMS.MEDICINE.REC.1397.154).

References

  1. 1.
    Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J (2010) Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol 62:177–188.  https://doi.org/10.1016/j.jaad.2009.10.032 (Quiz 189–190) CrossRefGoogle Scholar
  2. 2.
    Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J (2010) Alopecia areata update: part II. Treatment. J Am Acad Dermatol 62:191–202.  https://doi.org/10.1016/j.jaad.2009.10.031 (Quiz 203–194) CrossRefGoogle Scholar
  3. 3.
    Berth-Jones J, Hutchinson PE (1991) Treatment of alopecia totalis with a combination of inosine pranobex and diphencyprone compared to each treatment alone. Clin Exp Dermatol 16:172–175CrossRefGoogle Scholar
  4. 4.
    Buckley DA, Du Vivier AW (2001) The therapeutic use of topical contact sensitizers in benign dermatoses. Br J Dermatol 145:385–405CrossRefGoogle Scholar
  5. 5.
    Dall’oglio F, Nasca MR, Musumeci ML, La Torre G, Ricciardi G, Potenza C, Micali G (2005) Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial. J Dermatol Treat 16:10–14.  https://doi.org/10.1080/09546630410023601 CrossRefGoogle Scholar
  6. 6.
    Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J (2008) Interventions for alopecia areata. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.cd004413.pub2 Google Scholar
  7. 7.
    Durdu M, Özcan D, Baba M, Seçkin D (2015) Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series. J Am Acad Dermatol 72:640–650.  https://doi.org/10.1016/j.jaad.2015.01.008 CrossRefGoogle Scholar
  8. 8.
    Gregoriou S, Papafragkaki D, Kontochristopoulos G, Rallis E, Kalogeromitros D, Rigopoulos D (2010) Cytokines and other mediators in alopecia areata. Media Inflamm 2010:928030.  https://doi.org/10.1155/2010/928030 CrossRefGoogle Scholar
  9. 9.
    Happle R, Hausen BM, Wiesner-Menzel L (1983) Diphencyprone in the treatment of alopecia areata. Acta Dermato Venereol 63:49–52Google Scholar
  10. 10.
    Herbst V, Zoller M, Kissling S, Wenzel E, Stutz N, Freyschmidt-Paul P (2006) Diphenylcyclopropenone treatment of alopecia areata induces apoptosis of perifollicular lymphocytes. Eur J Dermatol 16:537–542Google Scholar
  11. 11.
    Hunt N, McHale S (2005) The psychological impact of alopecia. BMJ 331:951–953.  https://doi.org/10.1136/bmj.331.7522.951 (Clinical research ed) CrossRefGoogle Scholar
  12. 12.
    Jang YH, Jung HJ, Moon SY, Lee WJ, Lee SJ, Lee WK, Kim DW (2017) Systematic review and quality analysis of studies on the efficacy of topical diphenylcyclopropenone treatment for alopecia areata. J Am Acad Dermatol 77:170–172.e171.  https://doi.org/10.1016/j.jaad.2017.03.015 CrossRefGoogle Scholar
  13. 13.
    Lamb RC, Young D, Holmes S (2016) Retrospective review of diphencyprone in the treatment of alopecia areata. Clin Exp Dermatol 41:352–358.  https://doi.org/10.1111/ced.12776 CrossRefGoogle Scholar
  14. 14.
    Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M (2012) British association of dermatologists’ guidelines for the management of alopecia areata 2012. Br J Dermatol 166:916–926.  https://doi.org/10.1111/j.1365-2133.2012.10955.x CrossRefGoogle Scholar
  15. 15.
    Muthuvel K (2011) Practicality in using diphenyl cyclo propenone for alopecia areata. Int J Trichol 3:96–97.  https://doi.org/10.4103/0974-7753.90816 CrossRefGoogle Scholar
  16. 16.
    Ngwanya MR, Gray NA, Gumedze F, Ndyenga A, Khumalo NP (2017) Higher concentrations of dithranol appear to induce hair growth even in severe alopecia areata. Dermatol Ther 30:e12500.  https://doi.org/10.1111/dth.12500 CrossRefGoogle Scholar
  17. 17.
    Karanovic S, Harries M, Kaur MR (2018) Diphenylcyclopropenone for alopecia areata: a UK survey. Br J Dermatol 179:514–515.  https://doi.org/10.1111/bjd.16489 Google Scholar
  18. 18.
    Schmoeckel C, Weissmann I, Plewig G, Braun-Falco O (1979) Treatment of alopecia areata by anthralin-induced dermatitis. Arch Dermatol 115:1254–1255CrossRefGoogle Scholar
  19. 19.
    Shapiro J, Tan J, Ho V, Abbott F, Tron V (1993) Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation. J Am Acad Dermatol 29:729–735CrossRefGoogle Scholar
  20. 20.
    Sotiriadis D, Patsatsi A, Lazaridou E, Kastanis A, Vakirlis E, Chrysomallis F (2007) Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata. Clin Exp Dermatol 32:48–51.  https://doi.org/10.1111/j.1365-2230.2006.02256.x Google Scholar
  21. 21.
    Spano F, Donovan JC (2015) Alopecia areata: part 2: treatment. Can Fam Physician 61:757–761Google Scholar
  22. 22.
    Sriphojanart T, Khunkhet S, Suchonwanit P (2017) A retrospective comparative study of the efficacy and safety of two regimens of diphenylcyclopropenone in the treatment of recalcitrant alopecia areata. Dermatol Rep.  https://doi.org/10.4081/dr.2017.7399 Google Scholar
  23. 23.
    Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, Shapiro J (2018) Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol 78:15–24.  https://doi.org/10.1016/j.jaad.2017.04.1142 CrossRefGoogle Scholar
  24. 24.
    Tang L, Cao L, Pelech S, Lui H, Shapiro J (2003) Cytokines and signal transduction pathways mediated by anthralin in alopecia areata-affected Dundee experimental balding rats. J Investig Dermatol Symp Proc 8:87–90.  https://doi.org/10.1046/j.1523-1747.2003.12178.x CrossRefGoogle Scholar
  25. 25.
    Tang L, Cao L, Sundberg JP, Lui H, Shapiro J (2004) Restoration of hair growth in mice with an alopecia areata-like disease using topical anthralin. Exp Dermatol 13:5–10.  https://doi.org/10.1111/j.0906-6705.2004.00098.x CrossRefGoogle Scholar
  26. 26.
    Tang L, Sundberg JP, Lui H, Shapiro J (2003) Old wine in new bottles: reviving old therapies for alopecia areata using rodent models. J Investig Dermatol Symp Proc 8:212–216.  https://doi.org/10.1046/j.1087-0024.2003.00812.x CrossRefGoogle Scholar
  27. 27.
    Wasylyszyn T, Borowska K (2017) Possible advantage of imiquimod and diphenylcyclopropenone combined treatment versus diphenylcyclopropenone alone: an observational study of nonresponder patients with alopecia areata. Australas J Dermatol 58:219–223.  https://doi.org/10.1111/ajd.12478 CrossRefGoogle Scholar
  28. 28.
    Wasylyszyn T, Kozlowski W, Zabielski SL (2007) Changes in distribution pattern of CD8 lymphocytes in the scalp in alopecia areata during treatment with diphencyprone. Arch Dermatol Res 299:231–237.  https://doi.org/10.1007/s00403-007-0759-4 CrossRefGoogle Scholar
  29. 29.
    Yoshimasu T, Furukawa F (2016) Modified immunotherapy for alopecia areata. Autoimmun Rev 15:664–667.  https://doi.org/10.1016/j.autrev.2016.02.021 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Dermatology, Razi HospitalTehran University of Medical Sciences (TUMS)TehranIran
  2. 2.Department of Dermatology, Imam Khomeini HospitalTehran University of Medical Sciences (TUMS)TehranIran

Personalised recommendations